Short-Term Efficacy of Botulinum Toxin A for Refractory Overactive Bladder in the Elderly Population

Wesley White, Ryan Pickens, Regula Doggweiler, Frederick A. Klein

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Purpose: We determined the efficacy of intravesical botulinum toxin A injection for refractory overactive bladder in elderly patients. Materials and Methods: Patients 75 years or older with refractory urinary urgency were prospectively evaluated and offered treatment of symptoms with botulinum toxin A. A voiding log was obtained and urodynamics were performed before treatment. Patients underwent injection of 200 U botulinum toxin A (Botox®) into the detrusor muscle at 20 sites under cystoscopic guidance. Patients were followed postoperatively for evidence and duration of success, and treatment related complications. Results: From January 2006 to June 2007, 18 females and 3 males with a mean age of 81.2 years (range 75 to 92) in whom detrusor overactivity was confirmed on urodynamics and who were refractory to or intolerant of antimuscarinics were treated with intravesical botulinum toxin A. Preoperatively the mean ± SD number of daily voids was 11.4 ± 1.67 and the mean number of pads per day was 4.0 ± 0.89. One month after treatment 16 of the 21 patients (76%) reported greater than 50% improvement in symptoms after 1 injection. Specifically there was a significant improvement in the mean number of voids per day (5.19 ± 0.83, p <0.001) and in the number of pads used daily (1.3 ± 0.60, p <0.001). Two of the remaining 5 patients demonstrated greater than 50% improvement following repeat injection, while 3 did not show improvement after 2 injections. Mean time to deterioration was 7.12 months. There were no treatment related complications. Conclusions: Intravesical botulinum toxin A for detrusor overactivity in the elderly population appears to be efficacious and durable. Given its low incidence of adverse events, it should be considered a viable treatment option in this population.

Original languageEnglish (US)
Pages (from-to)2522-2526
Number of pages5
JournalJournal of Urology
Volume180
Issue number6
DOIs
StatePublished - Dec 1 2008

Fingerprint

Overactive Urinary Bladder
Type A Botulinum Toxins
Injections
Population
Urodynamics
Therapeutics
Muscarinic Antagonists
Muscles
Incidence

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Short-Term Efficacy of Botulinum Toxin A for Refractory Overactive Bladder in the Elderly Population. / White, Wesley; Pickens, Ryan; Doggweiler, Regula; Klein, Frederick A.

In: Journal of Urology, Vol. 180, No. 6, 01.12.2008, p. 2522-2526.

Research output: Contribution to journalArticle

@article{84d13ea295bb469c94b3fefec32c9d02,
title = "Short-Term Efficacy of Botulinum Toxin A for Refractory Overactive Bladder in the Elderly Population",
abstract = "Purpose: We determined the efficacy of intravesical botulinum toxin A injection for refractory overactive bladder in elderly patients. Materials and Methods: Patients 75 years or older with refractory urinary urgency were prospectively evaluated and offered treatment of symptoms with botulinum toxin A. A voiding log was obtained and urodynamics were performed before treatment. Patients underwent injection of 200 U botulinum toxin A (Botox{\circledR}) into the detrusor muscle at 20 sites under cystoscopic guidance. Patients were followed postoperatively for evidence and duration of success, and treatment related complications. Results: From January 2006 to June 2007, 18 females and 3 males with a mean age of 81.2 years (range 75 to 92) in whom detrusor overactivity was confirmed on urodynamics and who were refractory to or intolerant of antimuscarinics were treated with intravesical botulinum toxin A. Preoperatively the mean ± SD number of daily voids was 11.4 ± 1.67 and the mean number of pads per day was 4.0 ± 0.89. One month after treatment 16 of the 21 patients (76{\%}) reported greater than 50{\%} improvement in symptoms after 1 injection. Specifically there was a significant improvement in the mean number of voids per day (5.19 ± 0.83, p <0.001) and in the number of pads used daily (1.3 ± 0.60, p <0.001). Two of the remaining 5 patients demonstrated greater than 50{\%} improvement following repeat injection, while 3 did not show improvement after 2 injections. Mean time to deterioration was 7.12 months. There were no treatment related complications. Conclusions: Intravesical botulinum toxin A for detrusor overactivity in the elderly population appears to be efficacious and durable. Given its low incidence of adverse events, it should be considered a viable treatment option in this population.",
author = "Wesley White and Ryan Pickens and Regula Doggweiler and Klein, {Frederick A.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1016/j.juro.2008.08.030",
language = "English (US)",
volume = "180",
pages = "2522--2526",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Short-Term Efficacy of Botulinum Toxin A for Refractory Overactive Bladder in the Elderly Population

AU - White, Wesley

AU - Pickens, Ryan

AU - Doggweiler, Regula

AU - Klein, Frederick A.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Purpose: We determined the efficacy of intravesical botulinum toxin A injection for refractory overactive bladder in elderly patients. Materials and Methods: Patients 75 years or older with refractory urinary urgency were prospectively evaluated and offered treatment of symptoms with botulinum toxin A. A voiding log was obtained and urodynamics were performed before treatment. Patients underwent injection of 200 U botulinum toxin A (Botox®) into the detrusor muscle at 20 sites under cystoscopic guidance. Patients were followed postoperatively for evidence and duration of success, and treatment related complications. Results: From January 2006 to June 2007, 18 females and 3 males with a mean age of 81.2 years (range 75 to 92) in whom detrusor overactivity was confirmed on urodynamics and who were refractory to or intolerant of antimuscarinics were treated with intravesical botulinum toxin A. Preoperatively the mean ± SD number of daily voids was 11.4 ± 1.67 and the mean number of pads per day was 4.0 ± 0.89. One month after treatment 16 of the 21 patients (76%) reported greater than 50% improvement in symptoms after 1 injection. Specifically there was a significant improvement in the mean number of voids per day (5.19 ± 0.83, p <0.001) and in the number of pads used daily (1.3 ± 0.60, p <0.001). Two of the remaining 5 patients demonstrated greater than 50% improvement following repeat injection, while 3 did not show improvement after 2 injections. Mean time to deterioration was 7.12 months. There were no treatment related complications. Conclusions: Intravesical botulinum toxin A for detrusor overactivity in the elderly population appears to be efficacious and durable. Given its low incidence of adverse events, it should be considered a viable treatment option in this population.

AB - Purpose: We determined the efficacy of intravesical botulinum toxin A injection for refractory overactive bladder in elderly patients. Materials and Methods: Patients 75 years or older with refractory urinary urgency were prospectively evaluated and offered treatment of symptoms with botulinum toxin A. A voiding log was obtained and urodynamics were performed before treatment. Patients underwent injection of 200 U botulinum toxin A (Botox®) into the detrusor muscle at 20 sites under cystoscopic guidance. Patients were followed postoperatively for evidence and duration of success, and treatment related complications. Results: From January 2006 to June 2007, 18 females and 3 males with a mean age of 81.2 years (range 75 to 92) in whom detrusor overactivity was confirmed on urodynamics and who were refractory to or intolerant of antimuscarinics were treated with intravesical botulinum toxin A. Preoperatively the mean ± SD number of daily voids was 11.4 ± 1.67 and the mean number of pads per day was 4.0 ± 0.89. One month after treatment 16 of the 21 patients (76%) reported greater than 50% improvement in symptoms after 1 injection. Specifically there was a significant improvement in the mean number of voids per day (5.19 ± 0.83, p <0.001) and in the number of pads used daily (1.3 ± 0.60, p <0.001). Two of the remaining 5 patients demonstrated greater than 50% improvement following repeat injection, while 3 did not show improvement after 2 injections. Mean time to deterioration was 7.12 months. There were no treatment related complications. Conclusions: Intravesical botulinum toxin A for detrusor overactivity in the elderly population appears to be efficacious and durable. Given its low incidence of adverse events, it should be considered a viable treatment option in this population.

UR - http://www.scopus.com/inward/record.url?scp=55549113878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549113878&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2008.08.030

DO - 10.1016/j.juro.2008.08.030

M3 - Article

VL - 180

SP - 2522

EP - 2526

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -